CTLA4 and metastatic melanoma: Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human mAb against CTLA-4, was approved by FDA for thetreatment of metastatic melanoma [204] and in patients with melanoma and preexisting auto immune disorders [205].